A Safety, Pharmacokinetic, and Pharmacodynamic Study of Once Daily Inhaled AZD8630 in Adults With Asthma
← catalyst calendarSponsored by AstraZeneca (industry) · AZN — their whole pipeline →. With Parexel.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Na · Double · Treatment
Enrollment
24actual
Sites
3
Country
Germany
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-01-28 | actual | When the study began enrolling |
| Primary completion | 2025-06-27 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-06-27 | actual | The whole study's end, after follow-up |
| First posted | 2025-01-28 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-10-03 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Asthma
Interventions
- Drug: AZD8630
- Other: Placebo
- Device: Saphira device
Primary outcomes
what the primary-completion date above is the date OFNumber of adverse events (AEs) and serious adverse events (SAEs)
measured From Screening (Day -28) to Follow up (Day 21)
Number of adverse events leading to discontinuation (DAEs)
measured From Day 1 to Day 14
Area under the plasma concentration curve from zero to the last quantifiable concentration (AUClast)
measured Day 1, Day 14 and Follow up (Day 21)
Maximum observed plasma (peak) drug concentration (Cmax)
measured Day 1, Day 14 and Follow up (Day 21)
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed